Basic Requip Information

• INN (International Nonproprietary Name): Ropinirole
• Brand Names Available In United Kingdom: Requip, Requip XL, Adartrel and generic ropinirole tablets and extended‑release tablets
• ATC Code: N04BC04 (Nervous system; Anti‑Parkinson drugs; Dopamine agonists; Selective dopamine agonists)
• Forms & Dosages: Immediate‑release tablets 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg; extended‑release tablets 2 mg, 4 mg, 6 mg, 8 mg, 12 mg
• Manufacturers In United Kingdom: Global suppliers include GlaxoSmithKline (original) and multiple generics manufacturers (Teva, Mylan, Sandoz, Accord, Sun Pharma)
• Registration Status In United Kingdom: Authorised in EU/UK markets (EMA/MHRA) and available as branded and generic preparations
• OTC / Rx Classification: Prescription drug (Rx) in all markets

Critical Warnings & Restrictions

High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)

Patients ask which groups need extra caution; this is the short checklist clinicians use.

Known hypersensitivity to ropinirole or excipients is an absolute contraindication.

Elderly patients often show greater sensitivity to dopaminergic side effects and require slower titration and closer monitoring for orthostatic hypotension and falls.

Severe hepatic impairment is a concern and severe cases are generally not recommended for treatment with ropinirole.

Severe renal impairment requires caution and possible dose adjustment as clinically indicated.

A history of psychosis, hallucinations or active psychiatric disease needs specialist review before starting a dopamine agonist.

Impulse‑control disorders or prior compulsive behaviours should prompt discussion of risks and closer monitoring.

Pregnancy and breastfeeding should be managed only if the expected benefit justifies potential risk; discuss with the prescriber.

Pre‑treatment screening checklist: review full medical history, current medicines (including OTC and herbal), psychiatric history and driving/employment safety risks.

Baseline measurements to record: sitting and standing blood pressure and a documented counselling note given to the patient.

Issue a patient alert card and document counselling on sleepiness, hallucinations and compulsive behaviours.

Report adverse events via the MHRA Yellow Card and arrange urgent review for hallucinations, sudden sleep episodes or new compulsive behaviours.

Interaction With Activities (Driving, Workplace Safety Under UK Law)

Ropinirole can cause somnolence and sudden sleep episodes; patients must be counselled about driving and machinery use.

Advise patients not to drive or operate heavy machinery until they know how ropinirole affects alertness.

Under UK law, drivers whose medication affects alertness should follow DVLA guidance and notify the DVLA if licence criteria are met.

• Do not drive if you feel sleepy or have had a sleep episode after starting ropinirole.
• Avoid alcohol while you are getting used to the medicine.
• Report any sudden sleep episodes or excessive daytime sleepiness to the prescriber immediately.

Q&A — “Can I Drive After Taking It In The UK?”

Not until you know how it affects you.

If you experience excessive sleepiness or sudden sleep episodes, do not drive and discuss fitness to drive with your prescriber and follow DVLA guidance.

Usage Basics

INN, Brand Names Available In The UK

Patients often search for brand names such as Requip or Requip XL when they are prescribed ropinirole.

Ropinirole is sold in immediate‑release tablets and extended‑release formulations branded as Requip XL and as multiple generics including Adartrel.

• Immediate‑release strengths: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg.
• Extended‑release strengths: 2 mg, 4 mg, 6 mg, 8 mg, 12 mg.

Legal Classification (POM, P, GSL)

Ropinirole is a prescription‑only medicine (POM) in UK markets and requires a valid prescription for dispensing.

Prescriptions may be issued on NHS paper or electronically via EPS and dispensed at community pharmacies such as Boots, LloydsPharmacy and Superdrug.

Pharmacist counselling is mandatory at supply and sale is only against a valid prescription.

• INN: ropinirole.
• POM: prescription‑only medicine.
• IR / XR: immediate‑release versus extended‑release options available.

Dosing Guide

Standard Regimens (NHS Guidelines)

Patients commonly want to know how dosing starts and how it will change over the first weeks.

For Parkinson’s disease the usual starting dose is 0.25 mg three times daily with slow weekly increases as tolerated to a typical maximum of 24 mg per day.

For restless legs syndrome start at 0.25 mg once daily taken 1–3 hours before bedtime and titrate gradually with a typical maximum of 4 mg daily.

Extended‑release formulations permit once‑daily dosing and often improve adherence for long‑term Parkinson’s therapy.

Adjustments For Comorbidities

Elderly patients should have slower titration with close monitoring of orthostatic blood pressure and falls risk.

Patients with hepatic impairment need dose reduction or avoidance in severe cases.

Renal impairment may require dose changes in severe disease; monitor clinically.

Children are not recommended to use ropinirole as safety and efficacy are not established for paediatric use.

Q&A — “What If I Miss A Dose?”

If you remember well before the next scheduled dose, take the missed dose; if it is almost time for the next dose, skip the missed dose.

Do not double up doses to make up for a missed one and contact your pharmacist or prescriber if unsure.

Interaction Chart

Food And Drinks (Alcohol, Tea/Coffee, Diet Habits)

Alcohol increases sedation and the risk of orthostatic hypotension; advise patients to avoid alcohol while adjusting to ropinirole.

Smoking induces CYP1A2 and can reduce ropinirole levels; stopping smoking may increase ropinirole exposure and clinical effects, so monitor symptoms during smoking changes.

Caffeine has limited direct interaction but can affect sleep and should be considered when patients report insomnia or fragmented sleep.

Common Drug Conflicts (MHRA Yellow Card Data)

Ropinirole is mainly metabolised by CYP1A2 and interacts with inhibitors and inducers of this enzyme system.

Counselling points: review all prescription, over‑the‑counter and herbal medicines; advise on smoking changes and alcohol avoidance; monitor for increased side effects when adding CYP1A2 inhibitors.

User Reports & Trends

Patients often report common problems early on and benefits over time.

• Common early effects during titration include nausea and dizziness.
• Many report improved motor control for Parkinson’s after dose optimisation.
• Daytime sleepiness and occasional sudden sleep episodes are troublesome for a minority.
• Impulse‑control disorders such as gambling or compulsive shopping are less common but serious when they occur.

Recommendation: log side effects with time, activity and dose and discuss with your GP or specialist promptly.

Encourage reporting suspected adverse reactions to the MHRA Yellow Card scheme and keep a simple checklist of what to record: time of dose, activity at onset, description of symptom and any co‑medication.

Access & Purchase Options

Boots, LloydsPharmacy, Superdrug

Major UK pharmacy chains dispense ropinirole on presentation of a valid prescription, and availability of specific brands or strengths may vary by branch.

Generics are widely stocked and community pharmacists provide mandatory counselling and medicines checks at supply.

Online Pharmacies And NHS E‑Prescriptions

NHS Electronic Prescription Service (EPS) supports secure e‑prescribing to a nominated pharmacy for convenient collection or dispensing.

Reputable online pharmacies in the UK require an NHS or private prescription and verify prescriber details before supply; avoid overseas sellers that do not verify prescriptions.

Note on cost and access: an NHS prescription charge applies in England per item unless the patient is exempt, while prescriptions are free in Scotland, Wales and Northern Ireland.

In our online pharmacy, requip is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Safe online purchase checklist: confirm UK registration, require a UK prescription, verify pharmacist contact details and read privacy and returns policy.

Mechanism & Pharmacology

Simplified Explanation

Ropinirole is a dopamine receptor agonist acting primarily at D2 and D3 receptors to replace or augment dopaminergic signalling in Parkinson’s disease.

It reduces the sensory and motor symptoms of restless legs syndrome by modulating dopaminergic pathways involved in limb sensations and motor control.

ATC code N04BC04 places it among selective dopamine agonists for anti‑Parkinson therapy.

Clinical Terms

• IR vs XR: immediate‑release tablets are typically dosed multiple times daily while extended‑release tablets such as Requip XL are dosed once daily for convenience.
• Metabolism: mainly via CYP1A2, which governs key drug interactions and is affected by smoking and certain medicines.

Indications & Off‑Label Uses

MHRA‑Approved Uses

Ropinirole is licensed for Parkinson’s disease and restless legs syndrome (RLS).

It can be used as monotherapy in early Parkinson’s or as an adjunct to levodopa where clinically indicated.

Off‑Label Practices In NHS And Private Care

Specialist clinics may use dopamine agonists selectively for particular movement disorder phenotypes or to manage motor fluctuations.

Clinicians sometimes choose a dopamine agonist rather than immediate levodopa in younger patients to delay levodopa‑induced dyskinesia, while balancing the increased risk of impulse‑control disorders.

• Approved uses: Parkinson’s disease, restless legs syndrome.
• Off‑label: selected movement disorder strategies documented with informed consent and monitoring.

Checklist for off‑label prescribing: review the evidence, document informed consent, and set a clear monitoring plan.

Key Clinical Findings

Clinical evidence and UK analyses support ropinirole’s benefit in improving motor symptoms in early Parkinson’s and reducing RLS symptom severity.

Extended‑release formulations improve adherence and reduce the burden of nocturnal dosing.

Safety signals consistently reported in trials and post‑marketing surveillance include nausea, dizziness and somnolence as common tolerability issues.

Serious but less frequent risks include hallucinations, sudden sleep episodes and impulse‑control disorders which require prompt reporting and review.

• Efficacy: improvement in motor symptoms and RLS severity when used at appropriate doses.
• Safety trade‑offs: tolerability issues versus symptomatic benefit must be weighed for each patient.

Recommended monitoring schedule: baseline review with blood pressure and psychiatric history, first follow‑up at 4–6 weeks after initiation, then periodic reviews as clinically required.

Clinicians should consult NICE guidance and MHRA safety updates when selecting therapy and document individual risk factors such as age, psychiatric history and hepatic function.

Alternatives Matrix

NHS Prescribing Alternatives (Comparison)

Pros And Cons Checklist

• Pramipexole: comparable efficacy but similar impulse‑control risks.
• Rotigotine: convenient transdermal delivery but watch for skin reactions.
• Levodopa: superior symptomatic control with a long‑term dyskinesia trade‑off.
• Choose an alternative based on patient age, motor symptom severity, comorbidity and likelihood of adherence.

Common Questions

Patients ask three frequent questions at pharmacy pick‑up.

• Will ropinirole make me sleepy? Yes; somnolence and rare sudden sleep episodes occur so avoid driving until effects are known.
• Can I stop it suddenly? No; do not stop abruptly without clinical guidance as tapering may be advised.
• Are generics the same as Requip? Generic ropinirole contains the same active ingredient and is widely available, though excipients and formulations can differ so monitor when switching brands.

Pharmacists should encourage patients to report side effects to the MHRA Yellow Card and to always keep an up‑to‑date medication record.

NHS Cost & Access Comparison Table

Patients frequently ask where to collect prescriptions and how costs differ by region.

Regional differences: prescriptions are free in Scotland, Wales and Northern Ireland while England operates an item charge unless the patient is exempt.

Common exemptions include under‑16s, under‑19s in full‑time education, pregnant women and those on qualifying benefits.

Registration & Regulation

MHRA Approval Process

Ropinirole is authorised in the EU/UK and has historical approval by the US FDA with generics available; branded Requip remains marketed in many countries.

The MHRA monitors safety via Yellow Card reporting and issues safety communications when required.

Prescribers should check the Summary of Product Characteristics and MHRA updates prior to switching brands or changing doses.

NHS Prescribing Framework

Prescribing follows NHS formularies and local trust policies with initiation often in secondary care such as neurology or geriatrics.

GPs may continue therapy under shared care arrangements following specialist advice.

• Licence and marketing authorisation are followed by ongoing pharmacovigilance.
• Clinicians should document informed consent and monitoring plans and report adverse events.

Storage & Handling

UK Household Storage (Cold/Damp Climate)

Store ropinirole in the original container, protected from light and moisture and out of the reach of children.

Recommended storage temperature is 20–25°C with permitted excursions between 15–30°C, so avoid bathrooms and other damp places in UK homes.

Keep tablets in a stable, dry cupboard away from radiators and windowsills where temperature and humidity fluctuate.

Guidance From NHS And Pharmacists

When travelling keep medicines in the original labelled container and carry a copy of the prescription or a clinic letter if available.

Dispose of unused or expired medicines at a pharmacy take‑back service rather than household waste.

In overdose seek emergency care immediately; symptoms can include agitation, hallucinations, vomiting and involuntary movements.

• Storage temp: 20–25°C (excursions 15–30°C).
• Transport: keep in original packaging with label.
• Disposal: return to pharmacy for safe disposal.

Guidelines For Proper Use

UK Pharmacist Counselling Style

Pharmacists should open with the reason for the medicine and expected timeline for benefit.

Counselling points include dosing schedule, whether the prescribed product is IR or XR, and common side effects such as nausea, dizziness and somnolence.

Advise patients to carry an alert card, avoid driving if sleepy and report any mood or behaviour changes promptly.

Provide written information and document the counselling interaction in the patient record.

NHS Patient Safety Advice

Recommend gradual titration and monitoring of blood pressure and mental state during initiation and dose changes.

Review concomitant medicines for CYP1A2 inhibitors or inducers and document a follow‑up plan at initiation, at 4–8 weeks and periodically thereafter.

Encourage patients to use NHS services such as GP, neurology clinics and pharmacists for dose changes and to report adverse events via the MHRA Yellow Card system.

• Primary care review at initiation.
• Follow‑up at 4–8 weeks after dose stabilised.
• Ongoing periodic monitoring as clinically indicated.

Delivery Across United Kingdom